Advertisement

Advertisement

OBIO Stock Latest News

Orchestra BioMed price target raised to $10 from $9 at Piper Sandler

The FlyOrchestra BioMed price target raised to $10 from $9 at Piper Sandler

Orchestra BioMed reports Q2 EPS (37c), consensus (38c)

PremiumThe Fly

Orchestra BioMed reports Q2 EPS (37c), consensus (38c)

12d ago

Orchestra BioMed joins Russell 3000, Russell 2000 Indexes

PremiumThe Fly

Orchestra BioMed joins Russell 3000, Russell 2000 Indexes

2M ago

Orchestra BioMed Shareholders Approve Directors and Incentive Plan

PremiumCompany Announcements

Orchestra BioMed Shareholders Approve Directors and Incentive Plan

2M ago

Orchestra BioMed price target lowered to $10 from $12 at B. Riley

PremiumThe Fly

Orchestra BioMed price target lowered to $10 from $12 at B. Riley

3M ago

Orchestra BioMed price target raised to $13 from $12 at Barclays

PremiumThe FlyOrchestra BioMed price target raised to $13 from $12 at Barclays

3M ago

Orchestra BioMed reports Q1 EPS (33c), consensus (44c)

The Fly

Orchestra BioMed reports Q1 EPS (33c), consensus (44c)

3M ago

Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline

The Fly

Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline

3M ago

Orchestra BioMed receives $15M payment from Ligand

PremiumThe Fly

Orchestra BioMed receives $15M payment from Ligand

4M ago

Orchestra granted additional breakthrough device designation for AVIM therapy

PremiumThe Fly

Orchestra granted additional breakthrough device designation for AVIM therapy

4M ago

Orchestra BioMed: Accelerating Pivotal Trials and Strengthened Liquidity Support Buy Rating and Long‑Term Growth Outlook

PremiumRatings

Orchestra BioMed: Accelerating Pivotal Trials and Strengthened Liquidity Support Buy Rating and Long‑Term Growth Outlook

5M ago

Midday Fly By: Dick’s Sporting, Dollar General report quarterly beats

PremiumThe Fly

Midday Fly By: Dick’s Sporting, Dollar General report quarterly beats

5M ago

Orchestra BioMed reports FY25 EPS ($1.11), consensus ($1.74)

PremiumThe FlyOrchestra BioMed reports FY25 EPS ($1.11), consensus ($1.74)

5M ago

Orchestra BioMed: Undervalued Cardiovascular Innovator Poised for Multi‑Year Catalyst Cycle

Ratings

Orchestra BioMed: Undervalued Cardiovascular Innovator Poised for Multi‑Year Catalyst Cycle

5M ago

Orchestra BioMed management to meet with B. Riley

The Fly

Orchestra BioMed management to meet with B. Riley

6M ago

Orchestra BioMed announces two presentations at THT, CRT 2026 meetings

PremiumThe Fly

Orchestra BioMed announces two presentations at THT, CRT 2026 meetings

6M ago

Orchestra BioMed Adopts 2026 Performance-Driven Executive Compensation Plan

PremiumCompany Announcements

Orchestra BioMed Adopts 2026 Performance-Driven Executive Compensation Plan

6M ago

Orchestra BioMed gains cash from Vivasure sale proceeds

PremiumCompany Announcements

Orchestra BioMed gains cash from Vivasure sale proceeds

7M ago

Orchestra BioMed to receive up to $21M in proceeds from Vivasure acquisition

PremiumThe Fly

Orchestra BioMed to receive up to $21M in proceeds from Vivasure acquisition

7M ago

Orchestra BioMed price target raised to $12 from $11 at Barclays

PremiumThe FlyOrchestra BioMed price target raised to $12 from $11 at Barclays

8M ago

Orchestra BioMed initiated with a Buy at TD Cowen

The Fly

Orchestra BioMed initiated with a Buy at TD Cowen

9M ago

Is OBIO a Buy, Before Earnings?

Pre-Earnings

Is OBIO a Buy, Before Earnings?

9M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >